UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants
PRINCETON, N.J., June 17, 2024 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and...
UroGen touts `unprecedented` data for gel-based bladder cancer therapy
UroGen Announces Unprecedented 82.3% Duration of Response at 12 Months in the ENVISION Trial Investigating UGN-102 as Potentially the First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
UroGen Pharma to Host UGN-102 Virtual Data Event on June 13, 2024
UroGen Pharma Appoints David Lin as New Chief Commercial Officer
UroGen Pharma to Present at the TD Cowen 5th Annual Oncology Innovation Summit
UroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business Highlights
UroGen Pharma to Participate at Upcoming Investor Conferences